Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.899
+0.011 (1.24%)
Nov 20, 2024, 4:00 PM EST - Market closed
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 130 employees as of December 31, 2023. The number of employees increased by 23 or 21.50% compared to the previous year.
Employees
130
Change (1Y)
23
Growth (1Y)
21.50%
Revenue / Employee
$115,146
Profits / Employee
-$444,823
Market Cap
36.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130 | 23 | 21.50% |
Dec 31, 2022 | 107 | 35 | 48.61% |
Dec 31, 2021 | 72 | 24 | 50.00% |
Dec 31, 2020 | 48 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Beyond Air | 107 |
Carisma Therapeutics | 107 |
NextCure | 82 |
Lumos Pharma | 33 |
Incannex Healthcare | 9 |
CERo Therapeutics Holdings | 9 |
Dyadic International | 7 |
Lexaria Bioscience | 5 |
BRNS News
- 5 days ago - Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion - GlobeNewsWire
- 5 days ago - Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - GlobeNewsWire
- 14 days ago - Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewsWire
- 5 months ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire
- 5 months ago - Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewsWire
- 6 months ago - Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 7 months ago - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewsWire